Breathing new life into an old target: pulmonary disease drugs for Parkinson’s disease therapy

Increases in α-synuclein protein expression are suspected to increase the risk of the development of Parkinson’s disease (PD). A recent study has demonstrated that β2-adrenergic receptor (β2AR) agonists decrease histone acetylation in the α-synuclein gene and suppress transcription. Coupled with the...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelmotilib, Hisham, West, Andrew B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649055/
https://www.ncbi.nlm.nih.gov/pubmed/29052536
http://dx.doi.org/10.1186/s13073-017-0483-4
_version_ 1783272491152572416
author Abdelmotilib, Hisham
West, Andrew B.
author_facet Abdelmotilib, Hisham
West, Andrew B.
author_sort Abdelmotilib, Hisham
collection PubMed
description Increases in α-synuclein protein expression are suspected to increase the risk of the development of Parkinson’s disease (PD). A recent study has demonstrated that β2-adrenergic receptor (β2AR) agonists decrease histone acetylation in the α-synuclein gene and suppress transcription. Coupled with the anti-inflammatory effects that are associated with β2AR activation, this two-pronged attack holds promise for PD treatment and the development of new therapeutic approaches for this disease.
format Online
Article
Text
id pubmed-5649055
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56490552017-10-26 Breathing new life into an old target: pulmonary disease drugs for Parkinson’s disease therapy Abdelmotilib, Hisham West, Andrew B. Genome Med Research Highlight Increases in α-synuclein protein expression are suspected to increase the risk of the development of Parkinson’s disease (PD). A recent study has demonstrated that β2-adrenergic receptor (β2AR) agonists decrease histone acetylation in the α-synuclein gene and suppress transcription. Coupled with the anti-inflammatory effects that are associated with β2AR activation, this two-pronged attack holds promise for PD treatment and the development of new therapeutic approaches for this disease. BioMed Central 2017-10-19 /pmc/articles/PMC5649055/ /pubmed/29052536 http://dx.doi.org/10.1186/s13073-017-0483-4 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Highlight
Abdelmotilib, Hisham
West, Andrew B.
Breathing new life into an old target: pulmonary disease drugs for Parkinson’s disease therapy
title Breathing new life into an old target: pulmonary disease drugs for Parkinson’s disease therapy
title_full Breathing new life into an old target: pulmonary disease drugs for Parkinson’s disease therapy
title_fullStr Breathing new life into an old target: pulmonary disease drugs for Parkinson’s disease therapy
title_full_unstemmed Breathing new life into an old target: pulmonary disease drugs for Parkinson’s disease therapy
title_short Breathing new life into an old target: pulmonary disease drugs for Parkinson’s disease therapy
title_sort breathing new life into an old target: pulmonary disease drugs for parkinson’s disease therapy
topic Research Highlight
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649055/
https://www.ncbi.nlm.nih.gov/pubmed/29052536
http://dx.doi.org/10.1186/s13073-017-0483-4
work_keys_str_mv AT abdelmotilibhisham breathingnewlifeintoanoldtargetpulmonarydiseasedrugsforparkinsonsdiseasetherapy
AT westandrewb breathingnewlifeintoanoldtargetpulmonarydiseasedrugsforparkinsonsdiseasetherapy

Ejemplares similares